Form 4: Atea Pharmaceuticals Director Barbara Gayle Duncan Reports Stock Transaction
SEC Form 4 Filing
Director Barbara Gayle Duncan reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.
Summary
- On June 16, 2024, Barbara Gayle Duncan, a director of Atea Pharmaceuticals, Inc. (AVIR), converted 33,150 restricted stock units into 33,150 shares of common stock.
- The transaction was reported on a Form 4 filing with the SEC.
- The restricted stock units converted on a one-for-one basis and were fully vested with no expiration date.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and are essential for maintaining market transparency and preventing insider trading.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the director's holdings.
- The conversion of restricted stock units into common stock could slightly increase the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 06/16/2024 | Date of transaction: conversion of restricted stock units to common stock |
| 06/18/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.